Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
NCT07463664

Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions

Led by The First Affiliated Hospital of Zhengzhou University · Updated on 2026-03-11

200

Participants Needed

18

Research Sites

87 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of this study is to evaluate the long-term efficacy and safety of drug-coated balloon (DCB) strategies, including DCB alone or hybrid strategies of DCB and drug-eluting stent (DES), compared to DES-only in patients with chronic total occlusion (CTO) after successful recanalization. Through a prospective, multicenter randomized controlled trial, we will directly compare the long-term outcomes of these two treatment strategies in CTO patients to fill the gap in existing research regarding direct comparative data between DCB and DES in CTO treatment. This study expects to provide high-quality evidence for optimizing CTO treatment, potentially improving treatment strategies in complex cases, reducing stent usage, lowering the risk of complications, and ultimately enhancing patient prognosis.

CONDITIONS

Official Title

Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient voluntarily participates and has provided written informed consent
  • Clinical indication for PCI of chronic total occlusion (symptoms or evidence of ischemia)
  • Target lesion is a de novo coronary artery
  • Angiographically confirmed CTO with TIMI grade 0 flow and occlusion duration ≥ 3 months
  • Successful guidewire crossing of the target CTO lesion during the index procedure
  • After vessel preparation: distal TIMI grade 3 flow restored; residual stenosis < 50%; no flow-limiting dissection or complications
  • Target vessel diameter between 2.25 mm and 4.0 mm
  • Lesion suitable for treatment with both DCB and DES strategies as judged by the operator
  • Able and willing to comply with study protocol and follow-up schedule
  • Female participants of childbearing potential have negative pregnancy test and agree to use contraception during study
Not Eligible

You will not qualify if you...

  • Target CTO lesion is culprit vessel of acute myocardial infarction
  • Cardiogenic shock
  • Severe heart failure (NYHA class IV) or left ventricular ejection fraction < 30%
  • Stroke or transient ischemic attack within the past 3 months
  • High bleeding risk or contraindication to dual antiplatelet therapy
  • Severe hepatic or renal impairment (eGFR < 30 ml/min/1.73m² or dialysis requirement)
  • Known hypersensitivity or contraindication to study medications, DCB/DES drug coatings, or device materials
  • Target lesion in unprotected left main coronary artery, saphenous vein graft, or arterial graft
  • Severe lesion calcification preventing adequate vessel expansion despite preparation
  • CTO within previously stented segment (in-stent restenosis or thrombosis)
  • Failed CTO recanalization during index procedure
  • Complications after vessel preparation requiring immediate stenting
  • Concurrent enrollment in another interventional trial interfering with study
  • Pregnancy or breastfeeding
  • Investigator judgment of unsuitability including anticipated poor protocol compliance

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 18 locations

1

Fuwai Hospital Chinese Academy of Medical Sciences (CAMS)

Beijing, Beijing Municipality, China, 100037

Not Yet Recruiting

2

Anyang District Hospital

Anyang, Henan, China, 455000

Actively Recruiting

3

The People's Hospital of Jiaozuo

Jiaozuo, Henan, China, 454002

Not Yet Recruiting

4

The second people's Hospital of Jiyuan

Jiyuan, Henan, China, 454000

Actively Recruiting

5

Huaihe Hospital of Henan University

Kaifeng, Henan, China, 475000

Actively Recruiting

6

Kaifeng Central Hospital

Kaifeng, Henan, China, 475000

Actively Recruiting

7

The First Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan, China, 471003

Actively Recruiting

8

Nanyang City Center Hospital

Nanyang, Henan, China, 473000

Not Yet Recruiting

9

The Second People's Hospital of Pingdingshan

Pingdingshan, Henan, China, 467000

Actively Recruiting

10

Puyang People's Hospital

Puyang, Henan, China, 457099

Actively Recruiting

11

Yellow River Sanmenxia hospital

Sanmenxia, Henan, China, 472000

Not Yet Recruiting

12

Xinyang Central Hospital

Xinyang, Henan, China, 464000

Not Yet Recruiting

13

The First Affiliated Hospital of Henan University of CM

Zhengzhou, Henan, China, 450000

Not Yet Recruiting

14

Zhengzhou Central Hospital

Zhengzhou, Henan, China, 450000

Not Yet Recruiting

15

People's Hospital of Zhengzhou

Zhengzhou, Henan, China, 450053

Not Yet Recruiting

16

Zhoukou Central Hospital

Zhoukou, Henan, China, 466000

Actively Recruiting

17

Jincheng People's Hospital

Jincheng, Shanxi, China, 048026

Actively Recruiting

18

Tianjin Fourth Central Hospital

Tianjin, Tianjin Municipality, China, 300074

Not Yet Recruiting

Loading map...

Research Team

L

Liang Pan, Doctor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here